SAN FRANCISCO, Dec. 11, 2017 /PRNewswire/ -- Founder and Chief Executive Officer of DotLab, Heather Bowerman, will be speaking at this year's Technology for Precision Health Summit (TPHS) Presented by Health 2.0. The conference will take place on December 12, 2017 in San Francisco, California, and will focus on how technology and big data are transforming healthcare.
DotLab has developed the first-ever non-invasive saliva test for endometriosis that confirms the presence of active disease. While one in ten women have endometriosis, the disease is often misdiagnosed, and even a correct diagnosis takes an average of ten years and five separate physician visits. This is largely because the only way to definitively diagnose endometriosis today is laparoscopic surgery, which physicians often delay because of its invasive nature, potential clinical risks, and significant cost of up to $20,000. The test, which determines the quantity of disease-specific microRNA biomarkers, has the potential to serve as the first-ever quantitative proxy for detecting the disease and monitoring endometriosis over time.
At the conference, Bowerman will be participating in a panel on new diagnostic tools and discussing how such tools, including biomarkers, are poised for impact and their clinical and consumer applications. The panel will be moderated by TPHS Conference Chair Linda Molnar and include the co-founders of Color Genomics and Helix, amongst others.
Previously, Bowerman was a management consultant at McKinsey and a science and technology policy associate at the White House under the first Obama administration, where she focused on the Strategy for American Innovation and the administration's flagship innovation-focused legislation, the America Invents Act. By training, Bowerman is a biomedical engineer; she was the Harvard nanotechnology teaching fellow for the graduate course series and a research fellow in commercialization at Harvard Medical School.
About DotLab: DotLab is a personalized medicine company that was founded in 2016 by Heather Bowerman and Hugh Taylor, MD. In the past year, the company has received awards from Goldman Sachs and the American Society of Reproductive Medicine. DotLab's first product, DotEndo, is a non-invasive saliva test for endometriosis, a chronic condition that affects one in ten women worldwide. For more information, please visit www.dotlab.com.
 Mihalyi A, et al. Hum Reprod. 2010;25(3):654–664.
 Nnoaham KE, et al. Fertil Steril. 2011;96(2):366–373.e8.
View original content with multimedia:http://www.prnewswire.com/news-releases/dotlab-ceo-to-speak-at-2017-technology-for-precision-health-summit-presented-by-health-20-300569801.html